Back to Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 1

SJR OA
CiteScore
Impact Factor

Neuropsychiatric Disease and Treatment

ISSN: 1178-2021


      

Archive: Volume 3, 2007


Letter: Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

Fumihiko Okada

Neuropsychiatric Disease and Treatment 2007, 3:181-182

Published Date: 15 March 2007

Letter: Direct metabolic effects of risperidone and olanzapine in Japanese schizophrenic patients

Takahiko Nagamine

Neuropsychiatric Disease and Treatment 2007, 3:177-179

Published Date: 15 March 2007

Aripiprazole treatment of Asperger’s syndrome in the acute psychiatric setting: case report

Luiz Dratcu, Gavin McKay, Vinod Singaravelu, Venkat Krishnamurthy

Neuropsychiatric Disease and Treatment 2007, 3:173-176

Published Date: 15 March 2007

A survey of five antidepressant properties influencing clinician’s treatment choices in MDD

George I Papakostas, Lindsay A Hallett, Juliana Smith, Eliana Tossani, Alessandra Mascarini, Alana M Burns, Robert J Birnbaum, Maurizio Fava, Jonathan E Alpert

Neuropsychiatric Disease and Treatment 2007, 3:169-172

Published Date: 15 March 2007

The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists

Michael A Shapiro, Yu Ling Chang, Sarah K Munson, Charles E Jacobson IV, Ramon L Rodriguez, Frank M Skidmore, Michael S Okun, Hubert H Fernandez

Neuropsychiatric Disease and Treatment 2007, 3:161-167

Published Date: 15 March 2007

One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters)

Eva Cešková, Prikryl Radovan, Kašpárek Tomáš, Kucerová Hana

Neuropsychiatric Disease and Treatment 2007, 3:153-160

Published Date: 15 March 2007

Prodromal non-motor symptoms of Parkinson’s disease

Clelia Pellicano, Dario Benincasa, Vincenzo Pisani, Francesca R Buttarelli, Morena Giovannelli, Francesco E Pontieri

Neuropsychiatric Disease and Treatment 2007, 3:145-151

Published Date: 15 March 2007

The schizophrenias, the neuroses and the covered wagon; a critical review

C Raymond Lake, Nathaniel Hurwitz

Neuropsychiatric Disease and Treatment 2007, 3:133-143

Published Date: 15 March 2007

Managing patient adherence and quality of life in epilepsy

Joanne Eatock, Gus A Baker

Neuropsychiatric Disease and Treatment 2007, 3:117-131

Published Date: 15 March 2007

Impaired cognition and attention in adults: pharmacological management strategies

Hervé Allain, Yvette Akwa, Lucette Lacomblez, Alain Lieury, Danièle Bentué-Ferrer

Neuropsychiatric Disease and Treatment 2007, 3:103-116

Published Date: 15 March 2007

Patterns of anterior cingulate activation in schizophrenia: a selective review

Rick Adams, Anthony S David

Neuropsychiatric Disease and Treatment 2007, 3:87-101

Published Date: 15 March 2007

Ziconotide: a review of its pharmacology and use in the treatment of pain

Joseph G McGivern

Neuropsychiatric Disease and Treatment 2007, 3:69-85

Published Date: 15 March 2007

Venlafaxine in the treatment of panic disorder

Martin A Katzman, Leslie Jacobs

Neuropsychiatric Disease and Treatment 2007, 3:59-67

Published Date: 15 March 2007

Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan

Teruhiko Higuchi, Mike Briley

Neuropsychiatric Disease and Treatment 2007, 3:41-58

Published Date: 15 March 2007

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long acting atypical antipsychotic

Pierre Chue

Neuropsychiatric Disease and Treatment 2007, 3:13-39

Published Date: 15 March 2007

Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)

Gerhard Kluger, Bettina Bauer

Neuropsychiatric Disease and Treatment 2007, 3:3-11

Published Date: 15 March 2007

Editorial: Pathological gambling and dopamine agonists: A phenotype? || FREE PAPER ||

Roger M Pinder

Neuropsychiatric Disease and Treatment 2007, 3:1-2

Published Date: 15 March 2007